ES2307381B1 - Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratami ento de alergias. - Google Patents
Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratami ento de alergias. Download PDFInfo
- Publication number
- ES2307381B1 ES2307381B1 ES200600955A ES200600955A ES2307381B1 ES 2307381 B1 ES2307381 B1 ES 2307381B1 ES 200600955 A ES200600955 A ES 200600955A ES 200600955 A ES200600955 A ES 200600955A ES 2307381 B1 ES2307381 B1 ES 2307381B1
- Authority
- ES
- Spain
- Prior art keywords
- par
- chimeric protein
- baselineskip
- judaica
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 150000002632 lipids Chemical class 0.000 title claims abstract description 8
- 230000007815 allergy Effects 0.000 title abstract description 43
- 230000000774 hypoallergenic effect Effects 0.000 title abstract description 16
- 102000004169 proteins and genes Human genes 0.000 title description 59
- 108090000623 proteins and genes Proteins 0.000 title description 59
- 239000000126 substance Substances 0.000 title description 2
- 239000013566 allergen Substances 0.000 claims abstract description 64
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 42
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 16
- 229920001184 polypeptide Polymers 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 230000027455 binding Effects 0.000 claims description 24
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 230000000813 microbial effect Effects 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 238000002955 isolation Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 108010078791 Carrier Proteins Proteins 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 240000006694 Stellaria media Species 0.000 claims 2
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 238000001742 protein purification Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 56
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 42
- 241001465379 Parietaria judaica Species 0.000 abstract description 42
- 238000000746 purification Methods 0.000 abstract description 11
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 56
- 208000026935 allergic disease Diseases 0.000 description 37
- 229960004784 allergens Drugs 0.000 description 35
- 208000010668 atopic eczema Diseases 0.000 description 28
- 239000000284 extract Substances 0.000 description 28
- 230000000172 allergic effect Effects 0.000 description 27
- 241000721467 Parietaria Species 0.000 description 19
- 238000009169 immunotherapy Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 18
- 230000002009 allergenic effect Effects 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 230000009257 reactivity Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000013598 vector Substances 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 240000007817 Olea europaea Species 0.000 description 7
- 206010033733 Papule Diseases 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 235000002725 Olea europaea Nutrition 0.000 description 5
- 239000008557 Parietaria judaica pollen Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 208000006673 asthma Diseases 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920002401 polyacrylamide Polymers 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 206010048908 Seasonal allergy Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 108010053156 lipid transfer protein Proteins 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000013573 pollen allergen Substances 0.000 description 4
- 201000004338 pollen allergy Diseases 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 3
- 240000006891 Artemisia vulgaris Species 0.000 description 3
- 244000043261 Hevea brasiliensis Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 235000004789 Rosa xanthina Nutrition 0.000 description 3
- 241000220222 Rosaceae Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 235000003826 Artemisia Nutrition 0.000 description 2
- 235000014036 Castanea Nutrition 0.000 description 2
- 241001070941 Castanea Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101000952180 Morus alba Mulatexin Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 244000170916 Paeonia officinalis Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- -1 WST-1 tetrazole salt Chemical class 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000009285 allergic inflammation Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000009052 artemisia Nutrition 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940046528 grass pollen Drugs 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 150000002411 histidines Chemical class 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000007233 immunological mechanism Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710196809 Non-specific lipid-transfer protein 1 Proteins 0.000 description 1
- 101710196810 Non-specific lipid-transfer protein 2 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000123969 Paeonia arietina Species 0.000 description 1
- 241000124497 Paeonia broteri Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241001499955 Plantago mauritanica Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000220221 Rosales Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100021588 Sterol carrier protein 2 Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical group 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
- 229940031826 phenolate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 230000010152 pollination Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 108010058363 sterol carrier proteins Proteins 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- XQTLDIFVVHJORV-UHFFFAOYSA-N tecnazene Chemical compound [O-][N+](=O)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl XQTLDIFVVHJORV-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/625—Extraction from natural sources
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200600955A ES2307381B1 (es) | 2006-04-12 | 2006-04-12 | Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratami ento de alergias. |
| EP11162616A EP2363409A1 (en) | 2006-04-12 | 2007-04-11 | Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies. |
| PT77343440T PT2007798E (pt) | 2006-04-12 | 2007-04-11 | Proteínas quiméricas hipoalergénicas pertencentes à família de transferência de lípidos de parietaria judaica para uso no tratamento de alergias |
| EP11162543.0A EP2392592B1 (en) | 2006-04-12 | 2007-04-11 | Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies. |
| JP2009504853A JP5373597B2 (ja) | 2006-04-12 | 2007-04-11 | アレルギー治療に用いるカベイラクサ（Ｐａｒｉｅｔａｒｉａｊｕｄａｉｃａ）の脂質輸送タンパク質ファミリーに属する低アレルギー誘導性のキメラタンパク質 |
| EP07734344.0A EP2007798B1 (en) | 2006-04-12 | 2007-04-11 | Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies |
| US12/296,260 US8697083B2 (en) | 2006-04-12 | 2007-04-11 | Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies |
| PCT/IB2007/001025 WO2007116316A1 (en) | 2006-04-12 | 2007-04-11 | Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies |
| CN2007800133849A CN101421296B (zh) | 2006-04-12 | 2007-04-11 | 用于治疗过敏的属于欧蓍草（Parietaria judaica）脂质转移家族的低变应原的嵌合蛋白质 |
| BRPI0710649-1A BRPI0710649A2 (pt) | 2006-04-12 | 2007-04-11 | proteìnas quiméricas hipoalergênicas pertencentes à famìlia de transferência lipìdica de parietaria judaica para uso no tratamento de alergias |
| CN201210468984.7A CN103059140B (zh) | 2006-04-12 | 2007-04-11 | 用于治疗过敏的属于欧蓍草(Parietaria judaica)脂质转移家族的低变应原的嵌合蛋白质 |
| MX2008013050A MX2008013050A (es) | 2006-04-12 | 2007-04-11 | Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratamiento de alergias. |
| CA2646900A CA2646900C (en) | 2006-04-12 | 2007-04-11 | Hypoallergenic chimeric proteins belonging to the lipid transfer family of parietaria judaica for use in the treatment of allergies |
| ES07734344.0T ES2550705T3 (es) | 2006-04-12 | 2007-04-11 | Proteínas quiméricas hipoalergénicas pertenecientes a la familia de transferencia de lípidos de Parietaria judaica para usar en el tratamiento de alergias |
| JP2013141864A JP6148088B2 (ja) | 2006-04-12 | 2013-07-05 | アレルギー治療に用いるカベイラクサ（Ｐａｒｉｅｔａｒｉａｊｕｄａｉｃａ）の脂質輸送タンパク質ファミリーに属する低アレルギー誘導性のキメラタンパク質 |
| US14/198,293 US9522939B2 (en) | 2006-04-12 | 2014-03-05 | Hypoallergenic chimeric proteins belonging to the lipid transfer family of Parietaria judaica for use in the treatment of allergies |
| JP2016015356A JP2016104796A (ja) | 2006-04-12 | 2016-01-29 | アレルギー治療に用いるカベイラクサ（Ｐａｒｉｅｔａｒｉａｊｕｄａｉｃａ）の脂質輸送タンパク質ファミリーに属する低アレルギー誘導性のキメラタンパク質 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200600955A ES2307381B1 (es) | 2006-04-12 | 2006-04-12 | Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratami ento de alergias. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ES2307381A2 ES2307381A2 (es) | 2008-11-16 |
| ES2307381R ES2307381R (es) | 2008-12-01 |
| ES2307381B1 true ES2307381B1 (es) | 2009-10-23 |
Family
ID=38421459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200600955A Expired - Fee Related ES2307381B1 (es) | 2006-04-12 | 2006-04-12 | Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratami ento de alergias. |
| ES07734344.0T Active ES2550705T3 (es) | 2006-04-12 | 2007-04-11 | Proteínas quiméricas hipoalergénicas pertenecientes a la familia de transferencia de lípidos de Parietaria judaica para usar en el tratamiento de alergias |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07734344.0T Active ES2550705T3 (es) | 2006-04-12 | 2007-04-11 | Proteínas quiméricas hipoalergénicas pertenecientes a la familia de transferencia de lípidos de Parietaria judaica para usar en el tratamiento de alergias |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8697083B2 (enExample) |
| EP (3) | EP2392592B1 (enExample) |
| JP (3) | JP5373597B2 (enExample) |
| CN (2) | CN101421296B (enExample) |
| BR (1) | BRPI0710649A2 (enExample) |
| CA (1) | CA2646900C (enExample) |
| ES (2) | ES2307381B1 (enExample) |
| MX (1) | MX2008013050A (enExample) |
| PT (1) | PT2007798E (enExample) |
| WO (1) | WO2007116316A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2307381B1 (es) * | 2006-04-12 | 2009-10-23 | Bial Industrial Farmaceutica S.A. | Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratami ento de alergias. |
| IT1395735B1 (it) * | 2009-08-04 | 2012-10-19 | Lofarma Spa | Proteina ibrida ipoallergenica e suoi usi |
| RU2470298C2 (ru) * | 2011-04-01 | 2012-12-20 | Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" (ФБУН "Уфимский НИИ медицины труда и экологии человека") | Способ ранней (донозологической) диагностики развития сенсибилизации к аллергенам воздуха рабочей зоны птицеводческого комплекса |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085278A1 (en) * | 2004-02-27 | 2005-09-15 | Consiglio Nazionale Delle Ricerche | Fusion proteins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10037759A1 (de) | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
| IT1317905B1 (it) | 2000-09-11 | 2003-07-15 | Consiglio Nazionale Ricerche | Varianti di allergeni ns-ltps, loro usi e composizioni che lecomprendono. |
| IT1318690B1 (it) | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti dell'allergene maggiore par j 2 di parietaria judaica. |
| US20030175312A1 (en) * | 2000-11-16 | 2003-09-18 | Alk-Abello A/S | Novel mutant allergens |
| EP1221317A1 (en) * | 2000-12-28 | 2002-07-10 | SHAN-Beteiligungsgesellschaft m.b.H. | Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins |
| JP4538192B2 (ja) * | 2001-05-01 | 2010-09-08 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 免疫疾患を治療するための融合分子及び方法 |
| US7265208B2 (en) * | 2001-05-01 | 2007-09-04 | The Regents Of The University Of California | Fusion molecules and treatment of IgE-mediated allergic diseases |
| ATE307141T1 (de) | 2003-01-21 | 2005-11-15 | Biomay Prod & Handel | Verfahren zur vorbereitung von hypoallergenen mosaikproteine |
| ITRM20030247A1 (it) * | 2003-05-20 | 2004-11-21 | Bonura Angela | Varianti ipoallergeniche degli allergeni maggiori |
| AT501101B1 (de) * | 2004-12-02 | 2008-01-15 | Biomay Ag | Protein-allergen-derivat |
| ES2307381B1 (es) * | 2006-04-12 | 2009-10-23 | Bial Industrial Farmaceutica S.A. | Proteinas quimericas hipoalergenicas pertenecientes a la familia de transportadoras de lipidos de parietaria judaica utiles para el tratami ento de alergias. |
-
2006
- 2006-04-12 ES ES200600955A patent/ES2307381B1/es not_active Expired - Fee Related
-
2007
- 2007-04-11 EP EP11162543.0A patent/EP2392592B1/en not_active Not-in-force
- 2007-04-11 US US12/296,260 patent/US8697083B2/en not_active Expired - Fee Related
- 2007-04-11 WO PCT/IB2007/001025 patent/WO2007116316A1/en not_active Ceased
- 2007-04-11 MX MX2008013050A patent/MX2008013050A/es active IP Right Grant
- 2007-04-11 CA CA2646900A patent/CA2646900C/en not_active Expired - Fee Related
- 2007-04-11 EP EP11162616A patent/EP2363409A1/en not_active Withdrawn
- 2007-04-11 BR BRPI0710649-1A patent/BRPI0710649A2/pt not_active IP Right Cessation
- 2007-04-11 EP EP07734344.0A patent/EP2007798B1/en active Active
- 2007-04-11 CN CN2007800133849A patent/CN101421296B/zh not_active Expired - Fee Related
- 2007-04-11 PT PT77343440T patent/PT2007798E/pt unknown
- 2007-04-11 ES ES07734344.0T patent/ES2550705T3/es active Active
- 2007-04-11 JP JP2009504853A patent/JP5373597B2/ja not_active Expired - Fee Related
- 2007-04-11 CN CN201210468984.7A patent/CN103059140B/zh not_active Expired - Fee Related
-
2013
- 2013-07-05 JP JP2013141864A patent/JP6148088B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/198,293 patent/US9522939B2/en not_active Expired - Fee Related
-
2016
- 2016-01-29 JP JP2016015356A patent/JP2016104796A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005085278A1 (en) * | 2004-02-27 | 2005-09-15 | Consiglio Nazionale Delle Ricerche | Fusion proteins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same |
Non-Patent Citations (3)
| Title |
|---|
| ASTURIAS, J.A. et al. "{}Par j 1 and Par j 2, the major allergens from Parietaria judaica pollen, have similar immunoglobulin E epitopes"{}. CLINICAL AND EXPERIMENTAL ALLERGY. Abril 2003. Vol. 33, N$^{o}$. 4, páginas 518-524; todo el documento, especialmente Fig. 1"{}. * |
| COLOMBO, P. et al. "{}Identification of an immunodominant IgE epitope of the Parietaria judaica major allergen"{}. JOURNAL OF IMMUNOLOGY. 15.03.1998. Vol. 160, N$^{o}$. 6, páginas 2780-2785; todo el documento. * |
| COSTA, M.A. et al. "{}cDNA cloning, expression and primary structure of Par j I, a major allergen of Parietaria judaica pollen"{}. FEBS LETTERS. 1994. Vol. 341, páginas 182-186; Fig. 3. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2646900A1 (en) | 2007-10-18 |
| US20090304727A1 (en) | 2009-12-10 |
| US8697083B2 (en) | 2014-04-15 |
| EP2007798B1 (en) | 2015-09-30 |
| ES2550705T3 (es) | 2015-11-11 |
| CN101421296B (zh) | 2013-01-02 |
| CN101421296A (zh) | 2009-04-29 |
| MX2008013050A (es) | 2009-01-14 |
| PT2007798E (pt) | 2015-11-13 |
| JP2009533046A (ja) | 2009-09-17 |
| JP5373597B2 (ja) | 2013-12-18 |
| JP2013233149A (ja) | 2013-11-21 |
| CN103059140B (zh) | 2016-09-28 |
| JP2016104796A (ja) | 2016-06-09 |
| EP2392592B1 (en) | 2016-12-14 |
| CA2646900C (en) | 2016-06-14 |
| ES2307381R (es) | 2008-12-01 |
| BRPI0710649A2 (pt) | 2011-08-23 |
| CN103059140A (zh) | 2013-04-24 |
| EP2392592A1 (en) | 2011-12-07 |
| JP6148088B2 (ja) | 2017-06-14 |
| EP2007798A1 (en) | 2008-12-31 |
| EP2363409A1 (en) | 2011-09-07 |
| US20140286972A1 (en) | 2014-09-25 |
| ES2307381A2 (es) | 2008-11-16 |
| WO2007116316A1 (en) | 2007-10-18 |
| US9522939B2 (en) | 2016-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2698525T3 (es) | Transportador de vacuna | |
| CN104519896B (zh) | 用于治疗变态反应的核酸 | |
| ES2720140T3 (es) | Proteínas de fusión transportadoras de péptido como vacunas para alergias | |
| ES2638271T3 (es) | Proteínas híbridas hipoalergénicas de alérgenos de ácaros del grupo 1 y 2 principales para uso en el tratamiento de alergias | |
| ES2676058T3 (es) | Extractos de alérgenos | |
| Twaroch et al. | Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy | |
| Akinfenwa et al. | Preventive administration of non-allergenic Bet v 1 peptides reduces allergic sensitization to major birch pollen allergen, Bet v 1 | |
| González-Rioja et al. | Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy | |
| US9522939B2 (en) | Hypoallergenic chimeric proteins belonging to the lipid transfer family of Parietaria judaica for use in the treatment of allergies | |
| JP5566404B2 (ja) | カバノキ花粉アレルギーの処置のための連続重複ペプチド | |
| ES2634241T3 (es) | Nuevos alérgenos de trigo | |
| EP2607376A1 (en) | Hypoallergenic allergen derivatives of Pru p 3 for immunotherapy of IgE-mediated peach allergy | |
| JP2008504004A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Ref document number: 20081116 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20181010 |